Corrigendum: Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach(Front. Oncol., (2022), 11, (783803), 10.3389/fonc.2021.783803)
Journal
Frontiers in Oncology
Journal Volume
12
Date Issued
2022-04-20
Author(s)
Tai, Yee Kit
Chan, Karen Ka Wing
Fong, Charlene Hui Hua
Ramanan, Sharanya
Yap, Jasmine Lye Yee
Yin, Jocelyn Naixin
Yip, Yun Sheng
Tan, Wei Ren
Koh, Angele Pei Fern
Tan, Nguan Soon
Chan, Ching Wan
Li, Jing Ze
Fröhlich, Jürg
Franco-Obregón, Alfredo
Abstract
In the original article, there was a nonconsequential error in Figure 1 as published. A fileconcatenation error occurred within the FACS analysis software that implicated the scatter dotplots shown in Figure 1C. The corrected Figure 1 appears below.
Subjects
breast cancer
chemotherapy
chorioallantoic membrane
doxorubicin
EMT
patient-derived xenograft
PEMFs
TRPC1
Publisher
FRONTIERS MEDIA SA
Type
corrigendum